GeNeuro SA (GEM.F)
| Previous Close | 1.6650 |
| Open | 1.6800 |
| Bid | 1.8100 x 40000 |
| Ask | 2.0600 x 40000 |
| Day's Range | 1.6800 - 1.8050 |
| 52 Week Range | 0.8540 - 1.9000 |
| Volume | |
| Avg. Volume | 60 |
| Market Cap | 57.753M |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024
GENEVA, Switzerland, May 16, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing therapies for patients with neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study.
- Business Wire
GeNeuro Publishes its 2024 Universal Registration Document
GENEVA, Switzerland, May 02, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the "Autorité des Marchés Financiers (AMF)".
- Business Wire
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
GENEVA, April 30, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.
